Yu-Ting Chou • UCSF Profiles (original) (raw)

  1. Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies. Nat Commun. 2026 Feb 07. Manabe T, Bergo HC, Li Q, Wang TS, Severson P, Miller N, Lee C, Yay Donderici E, Zhang N, Wu W, Chou YT, Kerr DL, Allegakoen P, Grandinetti KB, Soroceanu L, Pelham RJ, Martin ES, Murphy EA, Khanna V, Neal JW, Chen CT, Kato S, Williams R, Bivona TG. PMID: 41654519.
  2. Temporal photoproximity labeling of ligand-activated EGFR neighborhoods using MultiMap. Nat Chem Biol. 2026 Feb; 22(2):192-204. Lin Z, Ngo W, Chou YT, Wu H, Susa KJ, Jun YW, Bivona TG, Doudna JA, Wells JA. PMID: 41254216; PMCID: PMC12858401.
    View in: PubMed Mentions: 2 Fields:
    Translation:HumansCells
  3. Prognostic and Monitoring Utility of Serum CEA in Lung Adenocarcinoma: Differential Roles in EGFR-TKI and Chemotherapy Treatments. Cancer Med. 2025 Sep; 14(17):e71170. Kuo YS, Zheng MY, Shieh YS, Huang TW, Chou YT. PMID: 40856433; PMCID: PMC12378701.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  4. Intrinsic PDL1 Signaling Modulates TGFBI-Mediated Growth Suppression in Lung Adenocarcinoma. Cancer Sci. 2025 Oct; 116(10):2737-2749. Nguyen TTN, Chen PY, Zheng MY, Lin TK, Wang CC, Chen YM, Chou YT. PMID: 40702751; PMCID: PMC12485868.
    View in: PubMed Mentions: 1 Fields:
    Translation:HumansCells
  5. Targeting Minimal Residual Disease. ANNUAL REVIEW OF CANCER BIOLOGY. 2025; 9:205-223. Yu-Ting Chou, Paul Allegakoen, and Trever G. Bivona. View Publication.
  6. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nat Commun. 2024 May 03; 15(1):3741. Haderk F, Chou YT, Cech L, Fernández-Méndez C, Yu J, Olivas V, Meraz IM, Barbosa Rabago D, Kerr DL, Gomez C, Allegakoen DV, Guan J, Shah KN, Herrington KA, Gbenedio OM, Nanjo S, Majidi M, Tamaki W, Pourmoghadam YK, Rotow JK, McCoach CE, Riess JW, Gutkind JS, Tang TT, Post L, Huang B, Santisteban P, Goodarzi H, Bandyopadhyay S, Kuo CJ, Roose JP, Wu W, Blakely CM, Roth JA, Bivona TG. PMID: 38702301; PMCID: PMC11068778.
    View in: PubMed Mentions: 49 Fields:
    Translation:HumansAnimalsCells
  7. Suppression of Ribose-5-Phosphate Isomerase a Induces ROS to Activate Autophagy, Apoptosis, and Cellular Senescence in Lung Cancer. Int J Mol Sci. 2022 Jul 17; 23(14). Nieh YC, Chou YT, Chou YT, Wang CY, Lin SX, Ciou SC, Yuh CH, Wang HD. PMID: 35887232; PMCID: PMC9322731.
    View in: PubMed Mentions: 8 Fields:
    Translation:HumansCells
  8. Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer. J Clin Invest. 2022 07 01; 132(13). Nanjo S, Wu W, Karachaliou N, Blakely CM, Suzuki J, Chou YT, Ali SM, Kerr DL, Olivas VR, Shue J, Rotow J, Mayekar MK, Haderk F, Chatterjee N, Urisman A, Yeo JC, Skanderup AJ, Tan AC, Tam WL, Arrieta O, Hosomichi K, Nishiyama A, Yano S, Kirichok Y, Tan DS, Rosell R, Okimoto RA, Bivona TG. PMID: 35579943; PMCID: PMC9246391.
    View in: PubMed Mentions: 36 Fields:
    Translation:HumansCells
  9. Inhibition of SHP2 as an approach to block RAS-driven cancers. Adv Cancer Res. 2022; 153:205-236. Chou YT, Bivona TG. PMID: 35101231.
    View in: PubMed Mentions: 10 Fields:
    Translation:HumansCells
  10. Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules. Cell. 2021 05 13; 184(10):2649-2664.e18. Tulpule A, Guan J, Neel DS, Allegakoen HR, Lin YP, Brown D, Chou YT, Heslin A, Chatterjee N, Perati S, Menon S, Nguyen TA, Debnath J, Ramirez AD, Shi X, Yang B, Feng S, Makhija S, Huang B, Bivona TG. PMID: 33848463; PMCID: PMC8127962.
    View in: PubMed Mentions: 107 Fields:
    Translation:HumansCells
  11. A mammalian Wnt5a-Ror2-Vangl2 axis controls the cytoskeleton and confers cellular properties required for alveologenesis. Elife. 2020 05 12; 9. Zhang K, Yao E, Lin C, Chou YT, Wong J, Li J, Wolters PJ, Chuang PT. PMID: 32394892; PMCID: PMC7217702.
    View in: PubMed Mentions: 29 Fields:
    Translation:HumansAnimalsCells
  12. Ribose-5-phosphate isomerase A overexpression promotes liver cancer development in transgenic zebrafish via activation of ERK and β-catenin pathways. Carcinogenesis. 2019 05 14; 40(3):461-473. Chou YT, Chen LY, Tsai SL, Tu HC, Lu JW, Ciou SC, Wang HD, Yuh CH. PMID: 30418535; PMCID: PMC6514454.
    View in: PubMed Mentions: 22 Fields:
    Translation:AnimalsCells
  13. Identification of a noncanonical function for ribose-5-phosphate isomerase A promotes colorectal cancer formation by stabilizing and activating β-catenin via a novel C-terminal domain. PLoS Biol. 2018 01; 16(1):e2003714. Chou YT, Jiang JK, Yang MH, Lu JW, Lin HK, Wang HD, Yuh CH. PMID: 29337987; PMCID: PMC5786329.
    View in: PubMed Mentions: 24 Fields:
    Translation:HumansAnimalsCells
  14. Up-regulation of golgi α-mannosidase IA and down-regulation of golgi α-mannosidase IC activates unfolded protein response during hepatocarcinogenesis. Hepatol Commun. 2017 05; 1(3):230-247. Tu HC, Hsiao YC, Yang WY, Tsai SL, Lin HK, Liao CY, Lu JW, Chou YT, Wang HD, Yuh CH. PMID: 29404456; PMCID: PMC5721452.
    View in: PubMed Mentions: 22 Fields:
  15. Ribose-5-phosphate isomerase A regulates hepatocarcinogenesis via PP2A and ERK signaling. Int J Cancer. 2015 Jul 01; 137(1):104-15. Ciou SC, Chou YT, Liu YL, Nieh YC, Lu JW, Huang SF, Chou YT, Cheng LH, Lo JF, Chen MJ, Yang MC, Yuh CH, Wang HD. PMID: 25429733.
    View in: PubMed Mentions: 33 Fields:
    Translation:HumansAnimalsCells

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

Start with: newest oldestInclude: line numbers double spacing all authors publication IDs